Table 4. Lipid and glucose management statuses and subsequent CVE risks.
| A | HR (95% CI) | ||
| Unadjusted model | Adjusted model 1 | Adjusted model 2 | |
| LDL-C, mg/dl | 1.20 (1.02 to 1.41)＊ | 1.25 (1.05 to 1.47)＊ | 1.23 (1.04 to 1.46)＊ |
| HDL-C, mg/dl | 0.90 (0.77 to 1.04) | 0.87 (0.74 to 1.03) | 0.90 (0.77 to 1.06) |
| TG, mg/dl | 1.05 (0.91 to 1.21) | 0.97 (0.82 to 1.14) | 0.97 (0.82 to 1.14) |
| Hemoglobin A1c, % | 1.09 (0.95 to 1.26) | 1.06 (0.92 to 1.23) | 1.05 (0.90 to 1.21) |
| B | sub-HR (95% CI) | ||
| Unadjusted model | Adjusted model 1 | Adjusted model 2 | |
| AOC for LDL-C ＞70 mg/dl | 1.17 (1.01 to 1.35)＊ | 1.18 (1.02 to 1.37)＊ | 1.22 (1.05 to 1.44)＊ |
| AOC for LDL-C ＞55 mg/dl | 1.18 (1.01 to 1.37)＊ | 1.19 (1.02 to 1.39)＊ | 1.25 (1.05 to 1.48)＊ |
| AOC for LDL-C ＞40 mg/dl | 1.19 (1.01 to 1.39)＊ | 1.20 (1.02 to 1.40)＊ | 1.26 (1.06 to 1.50)† |
| AOC for LDL-C ＞0 mg/dl | 1.19 (1.02 to 1.39)＊ | 1.20 (1.02 to 1.41)＊ | 1.27 (1.07 to 1.52)† |
| AOC for %LDL-C ＞50% | 1.14 (å0.98 to 1.33) | 1.13 (0.97 to 1.32) | 1.20 (0.97 to 1.47) |
| C | sub-HR (95% CI) | ||
| Unadjusted model | Adjusted model 1 | Adjusted model 2 | |
| AUC for HDL-C ＜40 mg/dl | 1.19 (1.03 to 1.37)＊ | 1.23 (1.07 to 1.40)† | 1.20 (1.05 to 1.37)† |
| AOC for TG ＞175 mg/dl | 1.03 (0.87 to 1.21) | 1.06 (0.92 to 1.23) | 1.08 (0.92 to 1.26) |
| AOC for HbA1c ＞7.0% | 0.99 (0.83 to 1.19) | 0.97 (0.80 to 1.18) | 0.90 (0.73 to 1.11) |
| D | sub-HR (95% CI) | ||
| Unadjusted model | Adjusted model 1 | Adjusted model 2 | |
| LDL-C at 2 months, mg/dl | 1.19 (1.03 to 1.37)＊ | 1.21 (1.06 to 1.40)† | 1.29 (1.10 to 1.52)† |
| %LDL-C at 2 months, % | 1.24 (1.06 to 1.44)† | 1.22 (1.05 to 1.43)＊ | 1.36 (1.10 to 1.68)† |
| ΔLDL-C from baseline to 2 months, mg/dl | 1.29 (1.09 to 1.52)† | 1.26 (1.06 to 1.50)† | 1.48 (1.16 to 1.89)† |
A) Standardized hazard ratios (HR) and 95% confidence interval (CI) were estimated by extended Cox regression models by including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), log-transformed Triglyceride (TG), and log-transformed hemoglobin A1c (HbA1c) as time-varying covariates. B) and C) Standardized sub-distribution hazard ratios (sub-HR) and 95% CI were estimated by flexible risk regression with Fine-Gray model using areas over/under the curve (AOC/AUC) during the early six months after coronary intervention. D) Sub-HR and 95% CI were estimated by risk regression with Fine-Gray model using LDL-C, %LDL-C, and ΔLDL-C. CVE = cardiovascular event. ＊p＜0.05, †p＜0.01.